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Various genetic diseases of blood cells have been
successfully treated with allogeneic hematopoietic stem cell
(HSC) transplantation (HSCT) (Table 1). Given that all mature
blood cells and their progenitors are derived from HSCs,
replacement of genetically defective HSCs with normal
donor HSCs replenishes the hematopoietic and lymphoid
systems with genetically normal blood cells.
The biology of HSCs makes them amenable to trans-
plantation. They can be isolated ex vivo from a donor by
marrow harvest, peripheral blood stem cell (PBSC) mobili-
zation, or umbilical cord blood collection; processed to
enrich them from the far more abundant mature cells;
manipulated; and transplanted by i.v. infusion. After trans-
plantation, HSCs can produce new blood cells of all lineages
for the life of the recipient, producing an enduring effect.
HSCs are highly generative, with each stem cell producing,
through the proliferation of a series of successively more
lineage-restricted progenitor cells, literally millions of
mature progeny cells. However, HSCs are rare in their native
settings, fragile with ex vivo manipulation, and mostly
quiescent, which may protect them from accumulating DNA
damage but makes their genetic manipulation more difﬁcult.
Currently, it is not possible to expand the numbers of
pluripotent HSCs in culture to any useful extent, although
efforts aimed at doing so are ongoing.
From more than 40 years of allogeneic HSCT practice,
we have learned several key concepts. Transplantation
outcomes vary by HSC source and disease-speciﬁc comor-
bidities. Results are generally better with matched sibling
donors than with all other allogeneic HSCT donor options
(ie, unrelated adult or cord blood donors, haploidentical
family donors), owing to immunologic complications of
graft-versus-host disease (GVHD) or graft rejection,
which may occur more frequently, with increasing disparity
for HLAs and minor antigens. Marrow and immune
ablation are usually provided with high-dose combination
chemotherapy regimens (eg, busulfan/cyclophosphamide or
busulfan/ﬂudarabine, with or without serotherapy, such as
antithymocyte globulin). Although fully ablativeFinancial disclosure: See Acknowledgment on page S68.
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engraftment, conditioning-associated toxicities are a major
cause of morbidity and mortality. Efforts to reduce the
intensity of conditioning have led to lower frequencies of
toxicity, but may be limited by the concurrent higher rates of
late graft failure and GVHD. The success of reduced-intensity
regimens for nonmalignant hematologic disease depends in
part on the minimum level of lineage-speciﬁc donor cells
required for correction of clinical symptoms, which varies for
different diseases.
HSCT is the standard of care for life-threatening primary
immune deﬁciencies, such as severe combined immune
deﬁciency (SCID), which is uniformly fatal without trans-
plantation. Since the late 1960s, HSCT has been performed in
patients with SCID using matched sibling donors without
previous conditioning with >90% survival at most centers
[1-3]. SCID is the ﬁrst disease for which matched unrelated
donor (MUD) bone marrow (1974) and haploidentical
(parental) bonemarrow (1976) were used in HSCT. Outcomes
of HSCT using donors other than matched sibling donors
have continued to improve over time but remain worse than
outcomes with matched sibling donors, owing to immuno-
logic reactions, delayed immune reconstitution, and in many
cases, the use of conditioning therapy before transplantation.
Typical disease-free survival rates after allogeneic HSCT
range from 65% to 75%, although there is a great deal of
variability based on approach and center experience.
Given the limitations of allogeneic HSCT for patients with
SCID lacking a matched sibling donor, gene therapy was ﬁrst
investigated for SCID, and SCID is the ﬁrst disorder for which
gene therapy was shown to be clinically efﬁcacious.
Sickle cell disease (SCD) has also been treated with allo-
geneic HSCT, although at a much lower rate than for SCID.
Patients with SCD present several additional challenges to
successful allogeneic HSCT. They are often alloimmunized as
a result of frequent transfusions, which may further increase
the risk of rejection over that in patients with an otherwise
normal immune system. They may also have SCD-related
organ impairments, which increase risks associated with
complications of conditioning and GVHD. In previously
reported series, matched sibling donor HSCT for SCD was
successful in w90% of cases, with a 5%-10% rate of non-
engraftment and SCD recurrence and a 5%-10% rate of
transplantation-related mortality [4,5]. HSCT is performed
less often in patients with SCD lacking a matched sibling
donor, because of the increased risks of immunologic rejec-
tion and GVHD.
Outcomes are continually improving for all types of
allogeneic HSCT in response to better donor matching,Transplantation.
Table 1
Genetic Diseases of Blood Cells Treated with Allogeneic HSCT
Cell Type Diseases
RBCs b-thalassemia, SCD
WBCs Lymphocyte defects: SCID, Wiskott-Aldrich syndrome,
leukocyte adhesion deﬁciency, X-HIM, HLH, IPEX
Neutrophil defects: CGD, Chediak-Higashi syndrome,
Shwachman-Diamond syndrome
Storage/metabolic diseases: Gaucher disease, ALD,
MLD, MPS, osteopetrosis
Platelets Amegakaryocytosis, Glanzmann thrombasthenia
Stem/progenitor
cells
Fanconi anemia, Diamond-Blackfan anemia,
cyclic neutropenia, Kostmann sundrome
Diseases in italics have been examined in clinical gene therapy trials.
X-HIM indicates X-linked immunodeﬁciency with hyper-IgM; HLH,
Hemophagocytic Lymphohistiocytosis; IPEX, immune dysregulation, poly-
endocrinopathy, enteropathy, X-linked; ALD, adrenoleukodystrophy; MLD,
metachromatic leukodystrophy; MPS, mucopolysaccharidosis.
* These studies followed the initial clinical trial of gene therapy for ADA-
deﬁcient SCID performed at the National Institutes of Health in 1990 in
which peripheral blood T cells were transduced.
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management strategies. Nevertheless, there remains signif-
icant room for improvement in the safety and efﬁcacy of
HSCT, to provide the beneﬁts of this therapy to the majority
of people affected by genetic blood cell diseases.
AUTOLOGOUS HSCT WITH GENE-MODIFIED HSC
The central hypothesis of gene therapy for genetic blood
cell diseases is that HSCT using gene-modiﬁed autologous
HSCs has similar beneﬁts as allogeneic HSCT, with fewer
immunologic complications. Effective gene modiﬁcation of
HSCs must be permanent to allow the introduced correction
to persist as the HSCs proliferate and produce their abundant
progeny. Efforts to date have focused on stable addition of
a replacement gene (cDNA, b-globin mini-locus, or genomic
segment) or in situmodiﬁcation of the endogenous gene. The
primary approach has been the integration of viral vectors of
the Retroviridae family that covalently insert their passenger
gene into the chromosome of the target HSCs. Transfection or
electroporation of plasmids or use of adenoviral or AAV
vectors for HSC modiﬁcation has yielded low efﬁciency and
mostly transient gene presence, and in some cases possibly
prohibitive cytotoxicity. In theory, an autonomous gene
cassette that is able to self-replicate fast enough to be
maintained in the cytoplasm of cells as they proliferate (eg,
an episomal plasmid or artiﬁcial chromosome) may be used
for HSC gene therapy, but none of suitable activity has yet
been produced.
Retroviridae that have been used for stable gene transfer
to HSCs include the g-retroviral vectors (typically derived
from the murine leukemia virus family), lentiviral vectors
(typically derived from HIV-1), and spumaviruses (typically
the human foamy virus). All of these viruses can be turned
into gene delivery vectors by removing the viral genes
encoding their structural and enzymatic proteins and
replacing them with the human transgene of interest. The
viral proteins needed for virion production can be provided in
trans during a packaging step, resulting in vectors that can
enter target cells once to integrate their genome payload, but
are incapable of producing new viruses in the target cell,
absolutely preventing viral replication and ongoing infection.
The past 2-3 decades have brought incremental improve-
ments in gene delivery technology, with vectors made
at higher titers and clinical-scale production methods
established, in parallel with the identiﬁcation of optimal
cytokines and culture methods for the process of HSC trans-
ductionwith vectors. These vectors can in many cases lead togene transfer to the majority of human HSCs being treated.
Ideally, everyHSCwould bemodiﬁedwith a single copyof the
corrective gene; however, Poisson distribution dictates that
efforts to increase the percentage of HSCs that are transduced
lead to an increased number of vector copies per transduced
cell, which may add a risk of genotoxicity. Thus, efﬁcient and
controlled gene modiﬁcation of HSCs remains one of the
central technical challenges to advancing effective gene
therapy for many conditions in which high percentages of
gene-corrected HSCs are required for clinical beneﬁt.
Gene modiﬁcation of a patient’s HSCs entails relatively
complex, patient-speciﬁc cell processing after HSC procure-
ment (through bone marrow harvest, PBSC mobilization
with leukapheresis, or cord blood collection). Performed
under current Good Manufacturing Practice conditions, the
HSCs are usually enriched by CD34 immunoafﬁnity selection,
then cultured for several days in a mixture of stimulating
cytokines (eg, ckit ligand, ﬂt-3 ligand, thrombopoietin) on an
extracellular matrix protein (eg, recombinant ﬁbronectin)
layer, with one or more additions of the gene delivery vector
to the cells after a prestimulation phase. The cells are then
formulated for i.v. infusion by multiple cell washes and
suspension in a medium such as plasmalyte. Before being
readministered, the cell product must meet predeﬁned
release criteria for viability and absence of microbiological
contamination. Further characterization (eg, colony forma-
tion, vector copy number by quantitative PCR, transgene
product expression) is done postinfusion on reserved
aliquots of the ﬁnal cell product. These procedures have been
established at multiple academic sites and are well within
the capabilities of clinical stem cell processing laboratories
that have current Good Manufacturing Practice procedures
and environments in place.
PRIMARY IMMUNE DEFICIENCIES
The initial attempts at autologous HSCT using gene
therapy (performed between approximately 1992 and 2006)
were directed against primary immune deﬁciencies,
including adenosine deaminase (ADA)-deﬁcient SCID,
X-linked SCID (XSCID), chronic granulomatous disease
(CGD), and leukocyte adhesion deﬁciency. These trials used
g-retroviral vectors to deliver the appropriate cDNA to HSCs
with the retroviral long terminal repeats (LTRs) containing
strong enhancers and promoters to drive transgene
expression.
ADA-Deﬁcient SCID
ADA deﬁciency was identiﬁed as a genetic cause of some
cases of human SCID (w15%) in the early 1970s, and normal
human ADA cDNA was cloned in the 1980s as retroviral
vector technology was developing, making this a logical ﬁrst
candidate disease for gene therapy. Initial trials of gene
therapy for ADA SCID using HSCs were performed in Italy, the
Netherlands, and the United States in the early 1990s, tar-
geting CD34þ cells from bone marrow and umbilical cord
blood* [6-8]. No cytoreductive conditioning was applied in
these ﬁrst studies, possibly because the selective survival and
ampliﬁcation advantage of ADA-replete lymphocytes might
have been sufﬁcient to allow clinically beneﬁcial immune
reconstitution with only low-level engraftment of gene-
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HSCs was obtained with the culture conditions used at the
time, and gene-corrected blood and marrow cells were
detected in subjects at only very low levels for short periods,
with no clinical effects realized.
Besides the incremental improvements in vector produc-
tion and CD34þ cell transduction conditions that were
developed subsequently, the major advance in gene therapy
for ADA-deﬁcient SCID was made by a group in Milan that
administered a nonmyeloablative dose of busulfan (4 mg/kg)
to subjects before reinfusion of HSCs corrected by an ADA
gene retroviral vector [9]. This relatively low dose of busulfan,
which was well tolerated clinically, increased engraftment of
gene-corrected HSCs to allow reconstitution of T and B cell
numbers and function and conferred protective immunity,
which has persisted for more than a decade to date [10].
Subsequent trials using the approach of nonmyeloablative
conditioning before reinfusion of retroviral vector-transduced
bone marrow CD34þ cells performed in the United Kingdom
and the United States reported similar clinical outcomes, with
best effects seen in patients with ADA-SCID treated in infancy
[11,12]. To date, a total of 40 subjects have been treated in the
3 trials, all of whom survived and most of whom attained
protective immune function as a result of the gene therapy.
There have been no instances of vector-related complications
in any of these patients, in sharp contrast to the results seen
in patients with other primary immune deﬁciency diseases,
for reasons not well understood. It can be stated that this
approach may be considered as a standard of care for ADA-
deﬁcient patients lacking a matched sibling donor, although
the total numbers of treated subjects and duration of follow-
up remain relatively low.
XSCID
Themost common genetic form of human SCID is X-linked
(XSCID), caused by functional absence of the common cyto-
kine receptor gamma chain (gc), which was cloned in the
mid-1990s. French investigators constructed retroviral
vectors carrying a normal human gc cDNA and initiated
a clinical trial targeting bonemarrow CD34þ cells, with HSCT
performed without cytoreductive conditioning. As they ﬁrst
reported in 2000, vigorous immune reconstitution was seen
in almost all subjects treated, with rapid increases in T
lymphocyte numbers and restoration of protective immunity
at a pace at least matching that seen with allogeneic HSCT
from matched sibling donors [13,14]. A similar trial con-
ducted in the United Kingdom also found prompt T cell
immune recovery, which persists to the present day [15].
A signiﬁcant complication developed in some of the
subjects treated in these 2 trials, however, with 5 of 20
developing a T lymphoproliferative disorder approximately
3-5 years after gene therapy [16]. This leukemia-like
complication responded to chemotherapy in 4 of the
subjects, who recovered with continued immune function
from the initial gene therapy, but 1 child died as a result of
the disease. Although this complication is indeed tragic,
a clear-cut beneﬁt was seen in many of the treated subjects,
and disease-free survival was w85%, at least equivalent to
that from the allogeneic transplant options available for
patients lacking a matched sibling donor. Other clinical trials
performed using g-retroviral vector-mediated gene transfer
to HSCs (granulocyte colony-stimulating factoremobilized
PBSCs) for the primary immune deﬁciencies CGD and
Wiskott-Aldrich syndrome had similar mixed results, with
clear-cut immune reconstitution in most subjects butleukoproliferative complications occurring in several treated
subjects a few years later [17,18].
INSERTIONAL ONCOGENESIS AND SAFER VECTORS
The wild-type, replication-competent g-retroviruses
from which the vectors were derived are known to cause
hematologic malignancies when they infect and proliferate
to high levels in neonatal mice, leading to multiple rounds of
integration into target cell genomes. This occurs through
a process of insertional oncogenesis (IO), in which the potent
transcriptional enhancer elements containedwithin the LTRs
of the retroviruses deregulate expression of cellular genes
that happen to be near their semirandom integration sites in
the genome. It was postulated that this event is very rare and
would not likely occur in the clinical setting, where
replication-incompetent vectors would only be able to enter
the genome once. Nevertheless, it is now recognized that IO
may occur with the numbers of integrants achieved in the
clinical setting.
The cases of leukoproliferative disease occurred just as
analytic methods were being developed that allowed their
detailed study. The development of efﬁcient PCR-based
methods to isolate the DNA sequences at the junction
between the vector provirus and the ﬂanking cellular chromo-
some (eg, linear ampliﬁcation-mediated (LAM)-PCR), as well as
methods for high-throughput sequencing of these junctional
fragments, and the decoding of the human genome sequence
allowed the analysis of vector integration sites and their
assignment to speciﬁc chromosomal locations even in complex
mixtures of cells with thousands of different integrants [19,20].
Different types of retroviral vectors are now known to
have characteristic integration preferences in the genome,
affected by chromatin structure and cellular factors that play
roles in guiding integrating vector genomes. The g-retroviral
vectors tend to integrate near the 50 ends of genes being
actively expressed; close proximity to the transcriptional
control elements of the genes allows their deregulation [21].
HIV-1ebased lentiviral vectors have an even higher predi-
lection to integrate into genes being actively transcribed,
although without the preference for the 50 ends of the genes.
Following these initial innate integration patterns, HSC
clones with vectors integrated near to cellular genes
controlling growth or survival may have these genes trans-
activated by the vector and experience increased growth and
begin a progression to ﬂank transformation.
Assays have been developed to quantify the potential of
vectors to induce IO, mainly using murine HSCs in clonal cell
culture or in bone marrow transplantation models [22,23].
From these studies, it is clear that the major factor deter-
mining the risk of a vector causing IO is the strength of the
enhancer elements that it contains, because these elements
may affect adjacent cellular transcription by acting on the
cell gene promoter. Other, less common mechanisms of IO
have been identiﬁed, including disruption of tumor-
suppressor genes by insertion directly into them or trunca-
tion of cellular gene transcripts by providing ectopic splicing
signals or polyadenylation signals, eliminating downstream
regulatory regions, such as microRNA-binding sites [24].
Stemming from this new understanding, a new genera-
tion of gene delivery vectors has been produced that do not
contain the potent LTR enhancers, but rather use cellular
gene promoters lacking strong enhancer activity (eg, PGK,
elongation factor a, WASP). In the experimental models of IO,
these new vectors exhibit signiﬁcantly lower, often unde-
tectable, ability to cause IO [25]. New trials are currently
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mine whether the clear-cut efﬁcacy that had been achieved
in earlier trials for primary immune deﬁciencies can be
maintained with decreased risks for the complications of IO
in XSCID, Wiskott-Aldrich syndrome, CGD, and chronic
granulomatous disease. In addition, successful trials have
been performed or are under way using lentiviral vectors for
several lysosomal storage or metabolic disorders amenable
to allogeneic HSCT, including X-adrenoleukodystrophy,
metachromatic leukodystrophy, globoid leukodystrophy, and
Hurler syndrome.
HEMOGLOBINOPATHIES
The major hemoglobinopathies b-thalassemia and SCD
have long been studied as candidates for treatment by gene
therapy. These disorders pose several unique challenges.
Transfer of a simple b-globin cDNA does not lead to the
sufﬁcient high-level expression needed to balance the
production of a-globin to ameliorate b-thalassemia or reduce
the percentage of bS in SCD. Expression of the b-globin gene
has been studied extensively in transgenic mice, and studies
have determined that a complex mini-gene is needed for
high-level erythroid-speciﬁc expression, containing the
exons and introns of the b-globin gene, 50 and 30 ﬂanking
regions with the transcriptional regulatory elements, and
portions of a series of DNA segments lying upstream from the
entire b-globin gene complex that play a role in opening the
regional chromatin to allow transcription in erythroid cells
(the locus-control region). When these b-globin mini-genes
are inserted into the murine germline, the resulting trans-
genic mice express the b-globin gene at levels sufﬁcient to
correct thalassemia. Attempts by multiple investigators to
carry these mini-genes in the g-retroviral vector were met
with failure, because the complex cassettes contained cryptic
splice sites and transcription termination signals and the
vectors underwent severe rearrangements, so that there was
very little delivery of intact expression units [26]. Sadelain
et al. [27] ﬁrst showed that HIV-1ebased lentiviral vectors
are capable of carrying these b-globin mini-genes intact,
owing in part to the presence of the HIV-1 rev-responsive
element in the vectors, which allows nuclear-to-cytoplasmic
export of intact full-length vector genomic transcripts during
packaging in the presence of the REV protein. Using b-globin
lentiviral vectors, these authors demonstrated correction in
murine b-thalassemic models [27].
Based on this work and similar studies by other investi-
gators, a clinical trial for b-thalassemia was initiated in
France using a lentiviral vector. One subject treated demon-
strated a progressive rise in hematocrit in the year after
treatment, but the mechanism behind this increase turned
out to be complex [28]. There was expansion of a single
vector-containing hematopoietic stem or progenitor cell
clone that contributed approximately one-third of the
hemoglobin produced. In this clone, the vector was inte-
grated into an intron of the HMGA2 gene and acted as a splice
site and transcriptional termination sequence, truncating the
HMGA2 transcript, eliminating the 30 end of the message that
conferred suppression by a microRNA. As a result of this, the
HMGA2 gene was overexpressed, which may underlie the
clonal expansion. This expansion has been stable over
several years to the present time and did result in a thera-
peutic effect, but is another example of unexpected geno-
toxicity from inserting vectors.
Several strategies have been developed for the treatment
of SCDwith gene therapy. Expression of normal b-globinmaybe beneﬁcial in SCD by counteracting the prosickling activity
of HbS, but very high expression levels are required to
produce a state similar to sickle cell trait. Expression of fetal
(g-) globin can prevent sickling at much lower molar
concentrations than b-globin, as seen in hereditary persis-
tence of fetal hemoglobin. Vectors have been created in
which the g-globin coding sequences have been embedded
in a b-globin expression cassette to achieve expression in
adult erythroid cells [29]. An alternative approach in which
the key amino acids of g-globin that confer antisickling
activity are introduced into a b-globin gene to produce
a novel “antisickling” protein was pioneered by Townes et al.
[30]. These approaches have not yet been tested in clinical
trials, but are advancing to the clinic.
Despite the improvements in b-globin gene transfer
afforded by lentiviral vectors, these vectors have relatively
low titers, owing in part to their relatively large size, which
impedes packaging of the vector genome and also may limit
reverse transcription in the target cell [31]. Producing sufﬁ-
cient quantities of clinical-grade b-globin lentiviral vectors to
perform clinical trials remains a challenge.
Globin gene transfer approaches for the treatment of
b-thalassemia and SCD face common challenges, but differ in
some regard. Higher levels of globin transgene expression
are required to treat b0-thalassemias compared with milder
forms of thalassemia, such as HbE thalassemia, and SCD, and
it remains uncertain whether all globin vectors express
sufﬁcient amounts of the therapeutic protein to cure severe
thalassemias at a low vector copy number [32]. Another
efﬁcacy issue that directly addresses the risk/beneﬁt is the
need for myeloablative conditioning, which may be required
in SCD to attain a sufﬁcient modiﬁcation of the erythroid
pool [32], but may represent an unnecessary risk in the
context of b-thalassemia [33].
IN SITU GENE CORRECTION
As discussed earlier, even though improved and poten-
tially safer gene delivery vectors have been developed,
semirandomly integrating vectors still may cause genotox-
icity (eg, gene disruption, trans-activation, truncation, trans-
splicing). An alternative approach to gene therapy is direct
modiﬁcation of endogenous genes harnessing cellular path-
ways of DNA repair. Homologous recombination (HR) is
a process through which double-stranded DNA breaks that
occur spontaneously or as a result of clastogenic agents are
repaired using a homologous segment of DNA (eg, from the
sister chromatid) as a template to replace the damaged
segment. HR-mediated gene modiﬁcation can be performed
to modify the sequence of an endogenous gene by adding to
cells high quantities of a DNA or RNA segment complemen-
tary to the target region but containing the desired sequence
change, for example, a segment homologous to the ﬁrst exon
of human b-globin with the wild-type sequence for the sixth
codon to replace the E6V mutation of bS-globin. However,
spontaneous gene conversion by HR is a very infrequent
event (on the order of 1 in 106 cells), which is far too low to
be of therapeutic value in primary HSCs (although it is
sufﬁcient to achieve targeted gene modiﬁcation when the
cell can be selected for and expanded, as in an embryonic
stem cell).
The frequency of HR can be greatly increased if a double-
stranded DNA break is introduced close to the target site,
followed by provision of the homologous donor template.
Sequence-speciﬁc DNA endonucleases have been developed
in several formats that can introduce a double-stranded DNA
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zinc ﬁnger nucleases, transcription activator-like effector
nucleases, and homing endonucleases, each of which carries
DNA sequence-speciﬁc recognition domains and an endo-
nuclease that will cleave the DNA sequence bound by the
recognition domains. Targeted genemodiﬁcation can thus be
performed in a two-step “hit and run” process in which
a site-speciﬁc double-stranded DNA break is produced and
the donor template acts as the homology-directed donor.
These genome-modifying tools can be used to produce
a variety of genome modiﬁcations. If only the endonuclease
is introduced without a donor, then the target gene may be
repaired by an error-prone DNA repair pathway, non-
homologous end joining (NHEJ), leading to disruption of the
activity of the target gene. This may be applied to disrupt
genes such as CCR5, which acts as a coreceptor for HIV-1
entry, Bcl11a, which represses fetal (g-) globin gene expres-
sion to ameliorate SCD, or other targets [34]. Addition of the
endonuclease plus a donor template with a few base pair
changes can be used to correct simple gene mutations.
Addition of the endonuclease plus a donor in which
sequences complementary to the target sequence ﬂank
a gene cassette can be used for site-speciﬁc gene insertion,
such as a marker gene for experimental studies, a cDNA to
correct gene mutations at any region of a gene, or an siRNA
cassette to repress expression of a cellular or viral gene.
The major potential advantages of gene correction
compared with ectopic gene addition is that the corrected
gene remains in its normal chromosomal context, and thus
its expression should occur in normal physiological patterns.
This is essential for treatment of conditions in which
expression of the relevant gene must be tightly regulated,
such as X-linked hyper-IgM syndrome (CD40 ligand deﬁ-
ciency), where constitutive expression of the CD40 ligand
gene can lead to lymphoproliferation [35]. Issues of IO should
be obviated, although gene modiﬁcation components could
cause other types of genotoxicity from off-target cutting or
insertion of the donor element.
These methods of genome engineering are still relatively
inefﬁcient. Competing DNA repair pathways in cells (HR
versus NHEJ) can decrease the frequency of the intended
modiﬁcation. Expression of the proteins mediating these
pathways varies over phases of the cell cycle and may have
low activity in mostly quiescent HSCs. The major limitation
remains the need to deliver multiple components (endonu-
clease, donor template) to primary cells at high levels, but
transiently. Several gene transfer methods have been
examined for these purposes, including transfection or
electroporation of plasmids or in vitro transcribedmRNA and
the use of adenoviral, adeno-associated viral, or integrase-
deﬁcient lentiviral vectors. Each of these delivery
approaches has pluses andminuses, but to date none had led
to gene correction frequencies in primary HSCs that can be
clinically useful.CHALLENGES
Gratifyingly, gene therapy is achieving progressively
more success as the technology advances, allowing treat-
ment of more diseases. The new generation of vectors in
current clinical trials may show improved safety and efﬁcacy.
There remain signiﬁcant challenges to advancing gene
therapy for more disorders, however. Continued improve-
ments inmethods for effective and safe genomemodiﬁcation
are needed. In addition, safer conditioning regimens or otherways to facilitate engraftment would be very advantageous
for both autologous and allogeneic HSCT.
Each disease (eg, >20 genetic etiologies of SCID) requires
speciﬁc development of gene-specsiﬁc vectors and the
developmental process that lead to clinical trials for that
disorder. HSCT is a high clinical acuity procedure carrying
signiﬁcant inherent risks from the conditioning required for
HSC engraftment (ie, toxicity and infection), graft failure, and
immunologic reactions. Gene therapy adds the risk of
suboptimal frequency of gene modiﬁcation of HSCs, poor
expression, and genome perturbation. Translational research
requires a well-trained staff of laboratory and clinical
investigators, which is difﬁcult to support on intermittent
project funding. There is a large regulatory burden for these
studies conducted under the Food and Drug Administration’s
Investigational NewDrug program, with additional oversight
from the National Institutes of Health’s Recombinant DNA
Advisory Committee and Institutional Biosafety Committees,
in addition to the standard Institutional Review Boards, Data
Safety Monitoring Board, Institutional Scientiﬁc Protocols
Review Committee, and so on.
Funding is needed in multiple stages over long develop-
mental time lines for preclinical work to establish proof of
principle and then Investigational New Drug work, toxi-
cology studies, clinical-grade vector production, and ﬁnally
clinical trials. Currently, individual grants must be obtained
for each of these steps, putting a project at risk for sudden
termination at any time. Fortunately, numerous funding
entities can contribute to the development of these trials,
including the National Heart, Lung and Blood Institute’s Gene
Therapy Resources Program and National Gene Vector Bio-
repository, Clinical and Translational Science Institutes fun-
ded by the new National Center for Advancing Translational
Sciences, and the Bridging Interventional Development Gaps
programs (successor to the Rapid Access to Intervention
Development program) and others. Ultimately, gene therapy
approaches will need to become more effective, safe, and
cost-effective before they can supplant allogeneic HSCT to
become a clinical standard of care.
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